CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC)

Yunhong Tian,Yong Peng,Huan Lyu,Jianlin Wu,Yichao Du,Cristian Chagas,Jiani Hu,Yunhong He,Shouliang Qi

doi:10.1186/s12885-018-5072-4

Abstract

BackgroundAccurate and early prognosis of disease is essential to clinical decision making, particularly in diseases, such as HCC, that are typically diagnosed at a late stage in the course of disease and therefore carry a poor prognosis. CDCA5 is a cell cycle regulatory protein that has shown prognostic value in several cancers.MethodsWe retrospectively evaluated 178 patients with HCC treated with curative liver resection between September 2009 and September 2012 at Nanchong Central Hospital in Nanchong, Sichuan Province, China. Patients were screened for their CDCA5 expression levels and assigned to either the high or low expression group. Patient demographics, comorbidities, clinicopathologic data, such as tumor microvascular invasion status and size, and long-term outcomes were compared between the two groups. The effect of CDCA5 on the proliferation of liver cancer cells was analyzed using in vitro and in vivo assays.ResultsThe present study found that increased CDCA5 expression was associated with increased tumor diameter and microvascular invasion in HCC. It was also found that CDCA5 overexpression may be associated with liver cancer cells. Additionally, this study confirmed that CDCA5 expression was increased in HCC tissue versus normal liver tissue, that CDCA5 expression was associated with decreased survival and that CDCA5 knockdown using shRNA led to cell cycle arrest in the G2/M phase.ConclusionsThese findings suggest that CDCA5 expression is associated with poor prognosis in patients with hepatocellular carcinoma.

Highlights

Accurate and early prognosis of disease is essential to clinical decision making, in diseases, such as hepatocellular carcinoma (HCC), that are typically diagnosed at a late stage in the course of disease and carry a poor prognosis
There were no significant differences in clinical features between the two groups in terms of gender, liver function, Child-Pugh score, alpha fetoprotein (AFP) level, platelet (PLT) count, antiviral therapy use, hepatitis B virus DNA (HBV-DNA) status, or Model-End-Stage liver disease (MELD) score (Table 1)
Pathological features Patients with CDCA5 overexpression had larger tumor diameters and a higher incidence of microvascular invasion compared with patients with decreased CDCA5 expression

Summary

Introduction

Accurate and early prognosis of disease is essential to clinical decision making, in diseases, such as HCC, that are typically diagnosed at a late stage in the course of disease and carry a poor prognosis. CDCA5 is a cell cycle regulatory protein that has shown prognostic value in several cancers. In 2015, the estimated total incidence of HCC in China was 466,100 patients, of which 343,700 were male and 122,300 were female. The estimated mortality was 422,100 people, with 310,600 males and 111,500 females affected [1, 2]. Cell-division cycle-associated 5 (CDCA5), known as sororin, is thought to play a critical role in ensuring the accurate separation of sister chromatids during the S and G2/M phases of the cell cycle through interactions with cohesin and cdk1 [5, 6]. CDCA5 has been shown to interact with ERK as well as cyclin E1, a critical regulator of the G1/Smitotic checkpoint [5,6,7].

Objectives

Methods

Results

Discussion

Conclusion